Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Additional Paid-In Capital : HK$597 Mil(As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Shenzhen Neptunus Interlong Bio-Technique Co Additional Paid-In Capital?

Shenzhen Neptunus Interlong Bio-Technique Co's quarterly additional paid-in capital increased from Sep. 2023 (HK$0 Mil) to Dec. 2023 (HK$607 Mil) but then stayed the same from Dec. 2023 (HK$607 Mil) to Jun. 2024 (HK$597 Mil).

Shenzhen Neptunus Interlong Bio-Technique Co's annual additional paid-in capital increased from Dec. 2021 (HK$0 Mil) to Dec. 2022 (HK$620 Mil) but then declined from Dec. 2022 (HK$620 Mil) to Dec. 2023 (HK$607 Mil).

Shenzhen Neptunus Interlong Bio-Technique Co Additional Paid-In Capital Historical Data

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Neptunus Interlong Bio-Technique Co Additional Paid-In Capital Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

619.60

606.88

Shenzhen Neptunus Interlong Bio-Technique Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	606.88	-	606.88	597.31

Shenzhen Neptunus Interlong Bio-Technique Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Shenzhen Neptunus Interlong Bio-Technique Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Shenzhen Neptunus Interlong Bio-Technique Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Neptunus Interlong Bio-Technique Co Ltd (HKSE:08329) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

95 Queensway, 18th Floor, United Centre, Admiralty, Hong Kong, HKG

Website

https://www.interlong.com

Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sales of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines; and the Sales and distribution of medicines and healthcare products. The majority of revenue is generated from the Manufacturing and selling of medicines.

Shenzhen Neptunus Interlong Bio-Technique Co Headlines

No Headlines